Citadel Advisors
INO icon

Citadel Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Citadel Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Sell
73,600
-310,600
-81% -$511K ﹤0.01% 11818
2025
Q4 		$669K Buy
384,200
+263,700
+219% +$581K ﹤0.01% 8306
2025
Q3 		$282K Buy
120,500
+55,100
+84% +$106K ﹤0.01% 10519
2025
Q2 		$133K Buy
65,400
+57,700
+749% +$111K ﹤0.01% 11068
2025
Q1 		$12.6K Sell
7,700
-15,140
-66% -$30.4K ﹤0.01% 13442
2024
Q4 		$41.8K Buy
22,840
+8,760
+62% +$38.8K ﹤0.01% 12574
2024
Q3 		$81.4K Sell
14,080
-1,560
-10% -$12.9K ﹤0.01% 11388
2024
Q2 		$126K Sell
15,640
-3,384
-18% -$35.6K ﹤0.01% 10581
2024
Q1 		$264K Sell
19,024
-12,126
-39% -$105K ﹤0.01% 9744
2023
Q4 		$191K Buy
31,150
+3,450
+12% +$17K ﹤0.01% 10029
2023
Q3 		$129K Sell
27,700
-2,567
-8% -$14.2K ﹤0.01% 10570
2023
Q2 		$162K Sell
30,267
-1,166
-4% -$9.4K ﹤0.01% 10213
2023
Q1 		$309K Sell
31,433
-12,084
-28% -$206K ﹤0.01% 9319
2022
Q4 		$815K Sell
43,517
-11,783
-21% -$267K ﹤0.01% 7214
2022
Q3 		$1.15M Buy
55,300
+8,975
+19% +$230K ﹤0.01% 6694
2022
Q2 		$962K Buy
46,325
+24,533
+113% +$691K ﹤0.01% 7106
2022
Q1 		$939K Sell
21,792
-41,833
-66% -$1.88M ﹤0.01% 7848
2021
Q4 		$3.81M Sell
63,625
-3,075
-5% -$246K ﹤0.01% 4850
2021
Q3 		$5.73M Buy
66,700
+9,592
+17% +$963K ﹤0.01% 4047
2021
Q2 		$6.35M Buy
57,108
+11,458
+25% +$1.1M ﹤0.01% 3938
2021
Q1 		$5.08M Buy
45,650
+3,242
+8% +$426K ﹤0.01% 4220
2020
Q4 		$4.5M Sell
42,408
-91,517
-68% -$12.2M ﹤0.01% 3863
2020
Q3 		$18.6M Buy
133,925
+35,108
+36% +$7.32M 0.01% 1645
2020
Q2 		$32M Buy
98,817
+25,975
+36% +$4.17M 0.01% 1114
2020
Q1 		$6.5M Buy
72,842
+69,967
+2,434% +$4.31M ﹤0.01% 2388
2019
Q4 		$114K Buy
+2,875
New +$86.5K ﹤0.01% 8494
2019
Q3 		– Sell
-1,458
Closed -$51K – 9456
2019
Q2 		$51K Sell
1,458
-134
-8% -$5.32K ﹤0.01% 8723
2019
Q1 		$71K Sell
1,592
-483
-23% -$24.3K ﹤0.01% 8679
2018
Q4 		$100K Sell
2,075
-517
-20% -$31.4K ﹤0.01% 8233
2018
Q3 		$173K Buy
2,592
+967
+60% +$53.8K ﹤0.01% 8321
2018
Q2 		$76K Buy
1,625
+392
+32% +$21.6K ﹤0.01% 8341
2018
Q1 		$70K Sell
1,233
-434
-26% -$23.5K ﹤0.01% 7834
2017
Q4 		$83K Sell
1,667
-125
-7% -$7.75K ﹤0.01% 7492
2017
Q3 		$136K Buy
1,792
+817
+84% +$60.8K ﹤0.01% 6920
2017
Q2 		$92K Sell
975
-158
-14% -$13.5K ﹤0.01% 6937
2017
Q1 		$90K Sell
1,133
-409
-27% -$32.6K ﹤0.01% 6901
2016
Q4 		$128K Sell
1,542
-708
-31% -$64K ﹤0.01% 6577
2016
Q3 		$252K Sell
2,250
-550
-20% -$60.8K ﹤0.01% 5956
2016
Q2 		$310K Sell
2,800
-5,025
-64% -$610K ﹤0.01% 5161
2016
Q1 		$818K Buy
7,825
+6,742
+623% +$521K ﹤0.01% 3716
2015
Q4 		$87K Sell
1,083
-500
-32% -$39.8K ﹤0.01% 6838
2015
Q3 		$110K Sell
1,583
-242
-13% -$21.1K ﹤0.01% 6867
2015
Q2 		$179K Sell
1,825
-267
-13% -$28.5K ﹤0.01% 6462
2015
Q1 		$205K Buy
2,092
+17
+0.8% +$1.65K ﹤0.01% 6150
2014
Q4 		$229K Sell
2,075
-1,250
-38% -$153K ﹤0.01% 5814
2014
Q3 		$393K Buy
3,325
+683
+26% +$85.1K ﹤0.01% 4932
2014
Q2 		$343K Buy
2,642
+2,519
+2,048% +$297K ﹤0.01% 4869
2014
Q1 		$20K Buy
+123
New +$17.7K ﹤0.01% 7290

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's INO Position: Q1 2026 in Review

Citadel Advisors opened a new position in Inovio Pharmaceuticals (INO) in Q1 2026: 286,352 shares worth $498K. The stake represents ﹤0.01% of the portfolio and ranks #9323 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INO as recently as Q3 2025.

Citadel Advisors first reported a position in INO in Q4 2013 and has held it in 32 quarters since. The position peaked at $9.29M in Q1 2021. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Citadel Advisors held 286,352 shares of Inovio Pharmaceuticals worth $498K as of Q1 2026.
  • Inovio Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9323 holding.
  • Citadel Advisors first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 32 quarters since.
  • Citadel Advisors's Inovio Pharmaceuticals position peaked at $9.29M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.